PEDIATRIC SURGERY *Update**
*Volume 65 No. 05 NOVEMBER 2025*

## Extraosseous Ewing's Sarcoma

Extraosseous Ewing's Sarcoma (EES) represents a distinct clinical and pathological entity within the Ewing Sarcoma Family of Tumors, arising in soft tissues without bone involvement. Though accounting for 20–30% of Ewing sarcoma cases, EES is rare, especially in the pediatric population. Its epidemiology, molecular underpinnings, clinical presentation, and therapeutic responses mirror, yet diverge in critical ways from, osseous Ewing sarcoma.

Pediatric EES exhibits a bimodal age distribution, peaking under five years and again in adolescence. It predominantly affects Caucasians, with a slight male preponderance. The incidence rate is roughly 0.4 per million children per year. Most tumors occur in the deep soft tissues of the trunk, thorax, paravertebral regions, or extremities. Unlike bone Ewing sarcoma, there appears to be no established racial or sex-based predisposition specific to EES, and familial or environmental risk factors remain unidentified.

Histologically, EES is a small round blue cell tumor that shares immunohistochemical and molecular features with osseous Ewing sarcoma, including strong CD99 membrane positivity and a high incidence of EWSR1 translocations. The most common fusion is EWSR1-FLI1 resulting from t(11;22)(q24;q12), present in about 85–90% of cases. Alternate fusions such as EWSR1-ERG or rare variants involving WT1 have also been documented. These genetic signatures are crucial not only for diagnosis but also for differentiating EES from morphologically similar entities such as rhabdomyosarcoma, lymphoma, or desmoplastic small round cell tumor.

Radiologically, EES typically presents as a large, heterogeneous soft tissue mass with aggressive features—irregular margins, necrotic or cystic areas, hemorrhage, and rich vascularity. CT and MRI are complementary; MRI is particularly useful in delineating tumor extent and neurovascular involvement. Unlike osseous Ewing sarcoma, periosteal reaction and cortical bone destruction are typically absent, although adjacent bone displacement or remodeling may be seen in long-standing cases.

Clinically, patients present with a painless, enlarging mass. Pain occurs in approximately one-third of cases, usually when adjacent structures are compressed. Constitutional symptoms are uncommon at presentation. Metastasis, present at diagnosis in up to 25% of cases, most frequently involves the lungs. Less commonly, bone and bone marrow metastases occur, especially in fusion-positive subtypes.

Prognostically, pediatric EES carries a better outlook than its osseous counterpart, with 5-year overall survival rates ranging from 65–85% in localized disease, though outcomes

vary significantly by site, tumor volume, and completeness of surgical resection. Prognosis declines sharply in metastatic or unresectable cases. Tumor volume greater than 200 mL is a recognized adverse prognostic factor. The thoracic region and pelvis are common primary sites with comparatively lower survival rates, likely due to challenges in achieving local control and the high propensity for pleural extension.

Treatment is multimodal, combining systemic chemotherapy with local control via surgery, radiation, or both. The standard chemotherapeutic regimen is interval-compressed VDC/IE (vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide and etoposide), typically delivered over 14–17 cycles. This backbone is supported by strong evidence from the Children's Oncology Group (COG) and other cooperative groups. The addition of vincristine-topotecan-cyclophosphamide (VTC) to standard chemotherapy failed to improve survival in randomized trials, reinforcing the efficacy of current regimens.

Surgery plays a more decisive role in EES than in osseous disease. Complete resection with negative margins is a robust positive prognostic factor. Tumors in resectable locations, such as the extremities or superficial trunk, achieve higher local control rates and better outcomes. In contrast, tumors arising in axial or deep pelvic locations often require multimodal local therapy, and when surgery is not feasible, radiotherapy is used either as a definitive or adjunct modality.

The radiosensitivity of EES enables its use for unresectable tumors or where negative margins cannot be achieved. However, long-term toxicity—especially in growing children—remains a concern, and thus radiation is reserved for selected cases. The evolution of conformal radiation and intensity-modulated techniques has allowed better dose delivery while limiting damage to adjacent critical structures.

Molecular profiling is reshaping risk stratification and treatment paradigms. The presence of EWSR1-FLI1 fusion, particularly type 1 fusions, appears to confer a more favorable prognosis than alternative or complex translocations. Fusion-negative cases, though rare, show heterogeneous biology and may behave more like other small round blue cell tumors. The role of targeted therapies remains investigational; IGF-1R inhibitors, PARP inhibitors, and epigenetic modulators have shown promise in early-phase trials but are not yet standard care.

Data on long-term survivorship in pediatric EES is limited but growing. A Dutch population-based analysis found that despite improvements in overall survival since the 1990s, adolescents and young adults continue to experience poorer outcomes compared to younger children. This disparity persists across stages, tumor sites, and tissue of origin. It is likely multifactorial—driven by biological, pharmacological, psychosocial, and healthcare access differences.

Meta-analyses reveal that recurrence rates in pediatric EES range from 25–35%, with secondary metastases in up to 16% of cases. Combined local therapy (surgery plus radiation) appears to offer superior local control compared to monotherapy, particularly for

tumors in challenging anatomical locations. Chemotherapy remains indispensable for systemic control, and its omission or delay correlates with worse outcomes.

Importantly, the literature emphasizes the need for centralized care in high-volume centers, where multidisciplinary teams can integrate advanced imaging, pathology, surgery, radiation, and supportive care. The rarity of EES, especially in the pediatric population, necessitates international collaboration to refine protocols, stratify risk, and identify molecular targets for personalized therapy.

In conclusion, extraosseous Ewing sarcoma in children remains a rare but highly aggressive malignancy requiring coordinated multimodal management. Advances in molecular diagnostics, risk-adapted therapies, and supportive care have improved survival, especially for localized disease. However, metastatic, and unresectable tumors remain formidable challenges. Ongoing trials, molecular stratification, and international cooperation will be key to optimizing outcomes and reducing long-term morbidity in this vulnerable population.

**References:**

1- Gurria JP, Dasgupta R. Rhabdomyosarcoma and Extraosseous Ewing Sarcoma. Children (Basel). 5(12):165, 2018

2- Leavey PJ, Laack NN, Krailo MD, Buxton A, Randall RL, DuBois SG, Reed DR, Grier HE, Hawkins DS, Pawel B, Nadel H, Womer RB, Letson GD, Bernstein M, Brown K, Maciej A, Chuba P, Ahmed AA, Indelicato DJ, Wang D, Marina N, Gorlick R, Janeway KA, Mascarenhas L. Phase III Trial Adding Vincristine-Topotecan-Cyclophosphamide to the Initial Treatment of Patients With Nonmetastatic Ewing Sarcoma: A Children's Oncology Group Report. J Clin Oncol. 2021 Dec 20;39(36):4029-4038. Erratum in: J Clin Oncol. 40(21):2393, 2022

3- Alexander A, Hunter K, Rubin M, Bhat AP. Extraosseous Ewing's Sarcoma: Pictorial Review of Imaging Findings, Differential Diagnosis, and Pathologic Correlation. Indian J Radiol Imaging. 31(1):203-209, 2021

4- Ghandour M, Lehner B, Klotz M, Geisbüsch A, Bollmann J, Renkawitz T, Horsch A. Extraosseous Ewing Sarcoma in Children: A Systematic Review and Meta-Analysis of Clinicodemographic Characteristics. Children (Basel). 9(12):1859, 2022

5- Ioannidou M, Tsotridou E, Samoladas E, Tragiannidis A, Kouskouras K, Sfougaris D, Spyridakis I, Foroulis C, Galli-Tsinopoulou A, Hatzipantelis E. Unusual Manifestation of Extraosseous Ewing Sarcoma: Report of 3 Cases. Balkan J Med Genet. 25(2):77-81, 2023

6- Ghandour M, Semaan K, Saad E, Horsch A, Abdallah R, Semaan D. Clinicodemographic characteristics of extraosseous ewing sarcoma: A comparative meta-analysis of pediatric and adult patients. J Orthop. 44:86-92, 2023

7- Schulpen M, Haveman LM, van der Heijden L, Kaal SEJ, Bramer JAM, Fajardo RD, de Haan JJ, Hiemcke-Jiwa LS, Ter Horst SAJ, Jutte PC, Schreuder HWB, Tromp JM, van der Graaf WTA, van de Sande MAJ, Gelderblom H, Merks JHM, Karim-Kos HE. The survival disparity between children and adolescents and young adults (AYAs) with Ewing sarcoma in the Netherlands did not change since the 1990s despite improved survival: A population-based study. Eur J Cancer. 208:114209, 2024

## Hepatic Mesenchymal Hamartoma

Hepatic mesenchymal hamartoma (HMH) is an uncommon but clinically significant benign liver tumor, predominantly affecting children under the age of three. Although histologically benign, its presentation, size, and potential for malignant transformation present unique diagnostic and therapeutic challenges. The condition is the second most common benign hepatic tumor in the pediatric population, following infantile hemangioma. It is believed to

arise from disorganized proliferation of primitive mesenchymal tissue within the liver, specifically in the periportal region, leading to a variable composition of stromal, ductal, vascular, and hepatic elements.

Most children with HMH present with nonspecific signs and symptoms. Abdominal distension is the most frequent clinical finding, often noticed by parents or healthcare providers due to a visible or palpable mass. Less commonly, patients may report or present with discomfort, vomiting, or systemic symptoms like fever or fatigue. In neonates, the mass effect can be significant enough to cause respiratory compromise or anemia due to rapid expansion or internal bleeding. Rarely, prenatal presentations have been documented, where fetal imaging reveals an abdominal mass leading to concerns such as polyhydramnios or preterm labor. In a number of prenatal cases, the tumor was mistaken for other liver abnormalities until postnatal evaluation clarified the diagnosis.

Diagnostic evaluation usually begins with imaging. Ultrasonography often shows a cystic or mixed cystic-solid hepatic mass, and its accessibility and safety make it the first-line imaging modality. On ultrasound, HMH may present with thin-walled, multiseptated cysts or heterogeneous areas depending on the tumor's internal composition. Color and power Doppler ultrasound may reveal minimal vascularity, which helps to distinguish it from more aggressive lesions. In computed tomography (CT) and magnetic resonance imaging (MRI), the mass typically appears as a large, well-circumscribed lesion with cystic and solid components. The classic "Swiss cheese" appearance—representing interspersed cystic and solid areas—is often observed on contrast-enhanced CT. Cystic regions usually show low attenuation, while solid portions may enhance heterogeneously. MRI further characterizes the lesion with high signal intensity in cystic areas on T2-weighted images, due to fluid accumulation, and variable signal on T1-weighted images depending on protein content.

The differential diagnosis is broad and includes hepatoblastoma, undifferentiated embryonal sarcoma of the liver (UESL), hemangioma, biliary cystadenoma, and parasitic infections like hydatid cysts. A particularly challenging scenario arises when alpha-fetoprotein (AFP) is mildly elevated, as elevated AFP levels are often associated with malignant liver tumors such as hepatoblastoma. However, mild to moderate AFP elevation has been observed in some cases of HMH, possibly due to regenerative hepatocytes within the lesion or associated inflammation. Hence, AFP levels alone cannot reliably distinguish between benign and malignant hepatic masses in children.

Histologically, HMH is composed of a mixture of myxoid mesenchymal stroma, malformed bile ducts, blood vessels, lymphatic channels, and entrapped hepatocytes. The stromal component is typically loose and edematous, with stellate-shaped mesenchymal cells, while the epithelial elements form ductal structures reminiscent of ductal plate malformations. In some areas, the lesion may display extensive cystic degeneration. The cysts are often not true epithelial-lined structures but rather pseudocysts arising from stromal liquefaction. Immunohistochemistry supports the diagnosis, with vimentin positivity

in mesenchymal cells, cytokeratin expression in ductal elements, and occasional positivity for desmin and smooth muscle actin.

Cytogenetic studies have provided insights into the underlying pathogenesis. Several cases of HMH have demonstrated chromosomal abnormalities, most notably translocations involving chromosome 19q13.4. This region includes the C19MC microRNA cluster, which is normally active in placental tissue but has been implicated in abnormal proliferation when dysregulated. Fusion genes involving MALAT1 at 11q13 and C19MC have been identified in both HMH and UESL, supporting the hypothesis that HMH and UESL may lie on a spectrum, with potential for malignant transformation under certain conditions. The presence of such cytogenetic similarities between benign and malignant pediatric liver tumors underscores the importance of thorough histological sampling, especially in recurrent or rapidly growing tumors.

Syndromic associations, although rare, have been reported. Some cases of HMH have been identified in children with Beckwith-Wiedemann Syndrome, a congenital overgrowth disorder associated with increased risk of various embryonal tumors. The connection may be mediated through shared pathways involving paternal uniparental disomy and imprinting defects at 11p15. In other reports, HMH has been found in conjunction with placental mesenchymal dysplasia, further supporting a developmental etiology linked to epigenetic abnormalities. Although earlier reports hypothesized that HMH is solely a developmental anomaly, accumulating molecular data suggest that it may represent a benign neoplasm with limited growth potential in most cases but with malignant potential in select circumstances.

Management of HMH depends on the size, symptoms, and extent of the lesion. Complete surgical resection remains the gold standard treatment and is typically curative. Enucleation or lobectomy is performed based on the tumor's location and involvement of hepatic structures. In some instances, particularly for giant or multicentric tumors, liver transplantation may be considered, though it is rarely necessary. For lesions causing acute mass effect, preoperative percutaneous aspiration of cystic fluid has been used as a temporizing measure to relieve symptoms and facilitate surgical planning. In select prenatal cases, aspiration has also been performed in utero to manage hydrops fetalis and allow continued gestation.

Advanced surgical planning tools have improved outcomes for complex cases. The application of three-dimensional (3D) simulation systems based on CT imaging has allowed for better preoperative visualization of tumor relationships with hepatic vasculature and bile ducts. Such systems facilitate precise anatomical liver resection, improving safety and minimizing blood loss. During surgery, technologies like intraoperative ultrasound and the Cavitron ultrasonic surgical aspirator (CUSA) are often employed to delineate margins and preserve hepatic function.

Postoperative prognosis for resected HMH is excellent, with most children experiencing full recovery and no recurrence. Follow-up imaging is generally recommended in the first few

years to monitor for potential recurrence, particularly in cases where resection margins were close or uncertain. In rare cases of incomplete excision, recurrence may occur and should be managed surgically. Isolated reports of malignant transformation to UESL years after incomplete resection of HMH highlight the need for vigilance in long-term follow-up.

The histologic distinction between HMH and early UESL is sometimes blurred, especially when areas of cellular atypia or increased mitotic activity are present. In such cases, deeper sampling and genetic analysis are advisable. While most UESLs appear de novo, several case studies have demonstrated malignant transformation of previously diagnosed HMH, confirmed by shared genetic abnormalities. This reinforces the importance of viewing HMH not as a uniformly benign lesion but as a biologically dynamic entity, especially when diagnosed beyond infancy or in atypical presentations.

Atypical cases continue to broaden our understanding of this rare tumor. For instance, some children over the age of five have been diagnosed with HMH, contradicting the usual age distribution. In one documented case, a five-year-old boy presented with a hepatic mass initially misdiagnosed as Caroli syndrome based on imaging, highlighting the diagnostic complexity and potential for overlap with congenital biliary disorders. In another case involving a preterm infant, the diagnosis of HMH was delayed due to initial suspicion of hemangioma and administration of propranolol therapy. The tumor continued to enlarge, leading to respiratory compromise and anemia, eventually requiring surgical resection with full recovery.

Despite being a benign tumor, HMH poses significant challenges due to its variable presentation, potential for confusion with malignant lesions, and occasional life-threatening mass effects. Its rarity means that many clinicians may only encounter a few cases over their careers, making awareness and understanding critical. Multimodal imaging, combined with histologic confirmation, remains the cornerstone of diagnosis. Innovations in imaging and surgical planning have improved safety and outcomes, while genetic research continues to uncover the underlying biology and connections with more aggressive pathologies.

In sum, hepatic mesenchymal hamartoma in children is a rare but important pediatric liver tumor, marked by diverse clinical and radiological manifestations. While most cases have an excellent prognosis with appropriate surgical management, the tumor's overlap with malignant entities and occasional genetic instability demands careful evaluation. Continued research into its molecular underpinnings and long-term outcomes will further clarify its nature and guide management strategies.

**References:**

1- Yen JB, Kong MS, Lin JN. Hepatic mesenchymal hamartoma. *J Paediatr Child Health.* 39(8):632–634, 2003

2. Kim SH, Kim WS, Cheon JE, Yoon HK, Kang GH, Kim IO, Yeon KM. Radiological spectrum of hepatic mesenchymal hamartoma in children. *Korean J Radiol.* 8(6):498–505, 2007

3. Zhao J, Zhou XJ, Zhu CZ, Wu Y, Wei B, Zhang G, Hao XW, Zhang H, Jiang Z, Dong Q. 3D simulation assisted resection of giant hepatic mesenchymal hamartoma in children. *Comput Assist Surg (Abingdon).* 22(1):54–59, 2017

4. Khan MR, Binkovitz LA, Smyrk TC, Potter DD Jr, Furuya KN. Mesenchymal Hamartoma in Children: A Diagnostic Challenge. *Case Rep Pediatr.* 2019:4132842, 2019
5. Martins-Filho SN, Putra J. Hepatic mesenchymal hamartoma and undifferentiated embryonal sarcoma of the liver: a pathologic review. *Hepat Oncol.* 7(2):HEP19, 2020
6. Wang Z, Mo J, Lv Z, Gong X, Hong W, Sheng Q. Giant hepatic mesenchymal hamartoma in a preterm newborn: a case report and literature review. *Am J Transl Res.* 14(12):8782–8787, 2022
7. Venkataraman S, Ur Rahman N, Sharma J, Bhagat A, Valsan A. Hepatic Mesenchymal Hamartoma With Elevated Alpha-Fetoprotein: A Diagnostic Dilemma. *Cureus.* 16(11):e74791, 2024

## Congenital H-Type Tracheoesophageal Fistula

Congenital H-type tracheoesophageal fistula (H-TEF) is a rare developmental anomaly accounting for approximately 4–5% of all congenital tracheoesophageal malformations. Unlike the more common types associated with esophageal atresia, H-TEF presents without interruption of the esophageal lumen, making the diagnosis both elusive and often delayed. Despite its rarity, the condition has serious implications for respiratory health, especially in infants and young children, and demands careful diagnostic strategy and surgical precision.

The clinical presentation of H-TEF is subtle yet persistent. Infants typically exhibit nonspecific symptoms such as choking during feeds, recurrent pneumonia, cyanosis, and respiratory distress. Older children may present with chronic cough or recurrent upper respiratory tract infections that are often misattributed to asthma or gastroesophageal reflux. In numerous cases, these symptoms result in prolonged diagnostic delays, with diagnosis occurring months to years after symptom onset. Some cases are not identified until adolescence or adulthood, underscoring the need for heightened clinical suspicion in any pediatric patient with recurrent respiratory illness and feeding difficulties.

Diagnostic approaches vary, but no single test guarantees early identification. Contrast esophagography remains a cornerstone technique but is frequently insufficient on its own. False negatives are not uncommon due to the small size or valvular nature of the fistulous tract. Repeating the study may be necessary, as demonstrated in multicenter reviews where two or even three studies were often needed to confirm the diagnosis. Bronchoscopy has emerged as the most definitive tool, offering direct visualization and the possibility of fistula cannulation, which aids surgical planning. When combined with fluoroscopy or contrast instillation, bronchoscopy can precisely locate the fistula and reveal coexisting anomalies such as tracheomalacia.

The majority of H-TEFs are located in the cervical region, often above the level of T2. Consequently, the preferred surgical approach is via a right cervical incision, which provides direct access with minimal morbidity. This technique allows for fistula division and primary repair, often with muscle interposition to reduce recurrence risk. In cases where the fistula lies lower in the thoracic cavity or is obscured by anatomical variations, a thoracic approach via thoracotomy or thoracoscopy is used. Thoracoscopic techniques are gaining favor due to their minimally invasive nature and favorable postoperative recovery profiles.

In a sizable series, thoracoscopic repair yielded no conversions to open surgery, low complication rates, and rapid discharge times.

Despite surgical advances, complications remain a concern. Vocal cord paralysis is the most commonly reported, with some series citing an incidence as high as 18.5%. This is often due to injury to the recurrent laryngeal nerve during dissection. In most cases, vocal cord function recovers over time, though in some, the damage is permanent and may necessitate secondary intervention. Other complications include fistula recurrence, reported in up to 8% of cases, as well as postoperative gastroesophageal reflux and, rarely, chylothorax. In delayed diagnoses, chronic inflammation and fibrosis around the fistula tract complicate surgical dissection and increase complication risk. In these instances, adjunctive measures like the application of hemostatic patches (e.g., TachoSil®) have been employed to reinforce suture lines and reduce leakage and recurrence.

The choice of surgical technique can significantly impact outcome. The cervical approach, though widely used, carries a higher risk of nerve injury compared to the thoracic route. Thoracoscopy, while technically demanding, offers better visualization and reduces tissue trauma. When performed by experienced surgeons, it has become a strong alternative to traditional open methods. Comparative reviews have highlighted the benefits of bronchoscopy-guided cannulation, which not only assists in localizing the fistula but also improves surgical precision and minimizes operative time.

Long-term outcomes are generally favorable when diagnosis and intervention are timely. Most patients experience complete resolution of symptoms following surgery. However, in the subset with delayed diagnosis, residual issues such as chronic lung disease or feeding difficulties may persist. Follow-up protocols should include vocal cord assessment, pulmonary function monitoring, and surveillance for recurrence. Standardizing these protocols could mitigate late morbidity and improve quality of life for these patients.

In conclusion, congenital H-type tracheoesophageal fistula poses significant diagnostic and therapeutic challenges. Its rarity, subtle presentation, and frequent diagnostic delays demand high clinical vigilance. Esophagography and bronchoscopy remain critical tools in confirming the diagnosis, with bronchoscopy proving most accurate. Surgical repair, ideally via a cervical or thoracoscopic approach, offers excellent outcomes when executed carefully. Future research should focus on refining surgical techniques, minimizing complications such as nerve injury, using neuromonitoring during closure, and exploring the role of adjunctive materials in high-risk or chronically inflamed cases. Early recognition and a structured, multidisciplinary management pathway remain key to improving prognosis in this complex but curable anomaly.

**References:**

1- Al-Salem AH, Mohaidly MA, Al-Buainain HM, Al-Jadaan S, Raboei E: Congenital H-type tracheoesophageal fistula: a national multicenter study. *Pediatr Surg Int.* 32(5):487-91, 2016

2**-** Edelman B, Selvaraj BJ, Joshi M, Patil U, Yarmush J: Anesthesia Practice: Review of Perioperative Management of H-Type Tracheoesophageal Fistula. *Anesthesiol Res Pract.* 2019:8621801, 2019

3- Sampat K, Losty PD: Diagnostic and management strategies for congenital H-type tracheoesophageal fistula: a systematic review. *Pediatr Surg Int.* 37(5):539-547, 2021

4- Tiwari C, Nagdeve N, Saoji R, Nama N, Khan MA: Congenital H-type tracheo-oesophageal fistula: An institutional review of a 10-year period. *J Mother Child.* 24(4):2-8, 2021
5- Toczewski K, Rygl M, Dzielendziak A, Frybova B, Patkowski D: Thoracoscopic repair of congenital isolated H-type tracheoesophageal fistula. *J Pediatr Surg.* 56(8):1386-1388, 2021
6- Anadolulu Aİ, Gerçel G, Gördü B, Arslan UE, Boybeyi Ö, Soyer T, Durakbaşa ÇU: Comparison of Diagnostic Methods, Surgical Approaches and Outcome for Congenital H-Type Tracheoesophageal Fistula: A Systematic Review. *J Pediatr Surg.* 60(8):162343, 2025
7- Pierucci UM, Paraboschi I, Zamana C, Canonica CPM, Guazco GIC, Bulfamante AM, Izzo F, Zirpoli S, Camporesi A, Pelizzo G: Delayed diagnosis of isolated congenital H-type tracheoesophageal fistula: a case report of surgical repair supported by TachoSil® as an adjunct in chronically inflamed tissues. *Transl Pediatr.* 14(7):1668-1674, 2025

---

***Edited by: Humberto Lugo-Vicente, MD, FACS, FAAP**
**Professor of Pediatric Surgery, UPR - School of Medicine, UCC School of Medicine & Ponce School of Medicine.**
**Pediatric Surgery, San Jorge Hospital.**
**Postal Address: P.O. Box 10426, San Juan, Puerto Rico USA 00922-0426.**
**Tel (787) 340-1868 E-mail:** ***pediatricsurgerypr@gmail.net***
**Internet: pedsurgeryupdate.com**

**** PSU 1993-2025***
**ISSN 1089-7739**